A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.

Details

Language :

English

ISSN :

10849785

Volume :

21

Issue :

2

Database :

Complementary Index

Journal :

Cancer Biotherapy & Radiopharmaceuticals

Publication Type :

Academic Journal

Accession number :

119805372

Full Text :

https://doi.org/10.1089/cbr.2006.21.88